MacroGenics | MGNX - Operating Expenses


MacroGenics reported $67M in Operating Expenses for its fiscal quarter ending in September of 2025.





Operating Expenses Change Date
AbbVie USD -2.64B 12.35B Sep/2025
Amgen USD 5.13B 1.39B Sep/2025
AstraZeneca USD 16.69B 5.74B Sep/2025
Biogen USD 1.88B 81.4M Sep/2025
Bristol-Myers Squibb USD 18.55B 10.06B Sep/2025
Daiichi Sankyo JPY 468.57B 15.34B Dec/2025
Eli Lilly USD 9.21B 677.8M Sep/2025
Genmab DKK 565M 38M Jun/2025
Geron USD 61.11M 376K Sep/2025
Gilead Sciences USD 4.26B 95M Sep/2025
J&J USD 18.97B 2.38B Dec/2025
MacroGenics USD 67M 8M Sep/2025
Merck USD 10.72B 1.28B Sep/2025
Pfizer USD 92.8B 82.47B Sep/2025
Regeneron Pharmaceuticals USD 2.99B 27.97B Dec/2025
Roche Holding CHF 21.01B 10.84B Dec/2025
Xencor USD 68.52M 8.26M Sep/2025